TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD
Brief Summary: The overall goal of this study is to compare the impact of a new Internet Dyspnea Self-Management Program (eDSMP) with an established face-to-face Dyspnea Self-Management Program (DSMP) in patients with COPD. The primary aim of the study is to test the following two hypotheses: 1. The eDSMP and the DSMP will have comparable improvements in the primary outcomes of shortness of breath (dyspnea) with activities of daily living (ADL), exercise adherence and performance, and pulmonary exacerbations (frequency and duration) at 3 and 6 months. 2. The eDSMP and the DSMP will have comparable improvements in the secondary outcomes of perception of support, self-efficacy for exercise and managing dyspnea, and health resource utilization at 3 and 6 months. This study is a randomized, longitudinal, repeated measures design with measurement times at 0, 3, and 6 months.


Options:
A: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention
B: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: half-yearly monitoring routine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: half-yearly monitoring routine; Assigned to Arm(s): A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Home based pulmonary rehabilitation with exercise | Arm Label: exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Home based pulmonary rehabilitation with exercise | Intervention Type: OTHER; Name: Home based pulmonary rehabilitation with exercise; Assigned to Arm(s): Placebo, exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD
Brief Summary: The overall goal of this study is to compare the impact of a new Internet Dyspnea Self-Management Program (eDSMP) with an established face-to-face Dyspnea Self-Management Program (DSMP) in patients with COPD. The primary aim of the study is to test the following two hypotheses: 1. The eDSMP and the DSMP will have comparable improvements in the primary outcomes of shortness of breath (dyspnea) with activities of daily living (ADL), exercise adherence and performance, and pulmonary exacerbations (frequency and duration) at 3 and 6 months. 2. The eDSMP and the DSMP will have comparable improvements in the secondary outcomes of perception of support, self-efficacy for exercise and managing dyspnea, and health resource utilization at 3 and 6 months. This study is a randomized, longitudinal, repeated measures design with measurement times at 0, 3, and 6 months.


Options:
A: Arm Label: MOBILE-A; Type: EXPERIMENTAL; Interventions: Behavioral: Coached exercise persistence intervention | Arm Label: MOBILE-B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Monitored exercise persistence intervention | Intervention Type: BEHAVIORAL; Name: Coached exercise persistence intervention; Assigned to Arm(s): MOBILE-A | Intervention Type: BEHAVIORAL; Name: Self-Monitored exercise persistence intervention; Assigned to Arm(s): MOBILE-B
B: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
C: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
D: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy
Brief Summary: SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with advanced solid tumors scheduled to receive chemotherapy with carboplatin and paclitaxel every 21 days. Patients will receive SB497115 on days 2-11 of each 21 day cycle for at least 2 cycles of chemotherapy and for a maximum of 8 cycles of chemotherapy.


Options:
A: Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Group A, Group B
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
D: Arm Label: Eltrombopag; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eltrombopag olamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Eltrombopag olamine; Assigned to Arm(s): Eltrombopag | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy
Brief Summary: SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with advanced solid tumors scheduled to receive chemotherapy with carboplatin and paclitaxel every 21 days. Patients will receive SB497115 on days 2-11 of each 21 day cycle for at least 2 cycles of chemotherapy and for a maximum of 8 cycles of chemotherapy.


Options:
A: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3
C: Arm Label: Eltrombopag; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Eltrombopag
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: See Detailed Description
Brief Summary: This study is a double-blind, randomized, placebo-controlled, parallel group, repeat-dose, study conducted in two parts (Part A and Part B) examining 30, 50, and 75 mg doses of SB-497115-GR as a treatment for patients with ITP who have failed prior therapy. The study is designed to determine the proportion of patients with a platelet count =50,000/µL after 42 days. In Part B, 99 newly-recruited subjects will be randomized to one of two dosing arms in a 2:1 ratio of active:placebo. During the 6 week study period, subjects will start on placebo or active drug (50 mg) and may have a dose increase to 75 mg based upon their platelet count at day 22.


Options:
A: Arm Label: Part A: Romiplostim 0.2 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 0.5 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 1.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 3 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 6 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 10 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part B: Romiplostim 1.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Romiplostim 3.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Romiplostim 6.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: Romiplostim 0.2 µg/kg, Part A: Romiplostim 0.5 µg/kg, Part A: Romiplostim 1.0 µg/kg, Part A: Romiplostim 10 µg/kg, Part A: Romiplostim 3 µg/kg, Part A: Romiplostim 6 µg/kg, Part B: Romiplostim 1.0 µg/kg, Part B: Romiplostim 3.0 µg/kg, Part B: Romiplostim 6.0 µg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B: Placebo
B: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Arm Label: Standard of Care; Type: OTHER; Interventions: Drug: Medical Standard of Care for ITP | Intervention Type: DRUG; Name: Medical Standard of Care for ITP; Assigned to Arm(s): Standard of Care | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim
C: Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): N/A
D: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone
Brief Summary: This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)


Options:
A: Arm Label: Placebo MDPI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDPI | Arm Label: Fp MDPI 25 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate | Arm Label: Fp MDPI 50 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate | Arm Label: FS MDPI 50/12.5 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Fp MDPI 25 mcg BID, Fp MDPI 50 mcg BID | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): FS MDPI 50/12.5 mcg BID | Intervention Type: DRUG; Name: Placebo MDPI; Assigned to Arm(s): Placebo MDPI
B: Intervention Type: DRUG; Name: fluticasone propionate/salmeterol powder; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate powder; Assigned to Arm(s): N/A
C: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast
D: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of AMG 386 in Adult Patients With Advanced Solid Tumors
Brief Summary: The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.


Options:
A: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
B: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib
C: Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept
D: Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]
Brief Summary: The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.


Options:
A: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
B: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Experimental
D: Arm Label: TLK286 in Combination with Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: TLK286 in Combination with Carboplatin | Arm Label: Doxorubisin HCl Liposome Injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxorubicin HCl Liposome Injection | Intervention Type: DRUG; Name: TLK286 in Combination with Carboplatin; Assigned to Arm(s): TLK286 in Combination with Carboplatin | Intervention Type: DRUG; Name: Doxorubicin HCl Liposome Injection; Assigned to Arm(s): Doxorubisin HCl Liposome Injection

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill any tumor cells that remain after surgery. It is not yet known whether whole breast radiation therapy is more effective than partial breast radiation therapy in treating breast cancer.

PURPOSE: This randomized phase III trial is studying whole breast radiation therapy to see how well it works compared to partial breast radiation therapy in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer.


Options:
A: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT
B: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy
C: Arm Label: Whole breast irradiation (WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole breast irradiation (WBI) | Arm Label: Partial breast irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation (APBI); Assigned to Arm(s): Partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Whole breast irradiation (WBI); Assigned to Arm(s): Whole breast irradiation (WBI)
D: Arm Label: Group 1: WBI; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole breast irradiation | Arm Label: Group 2: PBI; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation, Radiation: brachytherapy, Radiation: MammoSite or other single-entry intracavitary device | Intervention Type: RADIATION; Name: 3-dimensional conformal accelerated partial breast irradiation; Assigned to Arm(s): Group 2: PBI | Intervention Type: RADIATION; Name: brachytherapy; Assigned to Arm(s): Group 2: PBI | Intervention Type: RADIATION; Name: whole breast irradiation; Assigned to Arm(s): Group 1: WBI | Intervention Type: RADIATION; Name: MammoSite or other single-entry intracavitary device; Assigned to Arm(s): Group 2: PBI

Answer: D